The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Dominique Valeyre, Carlo Albera, Williamson Bradford, Ulrich Costabel, Talmadge King, Paul Noble, Steven Sahn, Roland du Bois
European Respiratory Journal 2012 40: P3159; DOI:
Dominique Valeyre
1Department of Medicine, Assistance Publique-Hôpitaux, Paris, France
Carlo Albera
2Clinical and Biological Sciences, University of Turin, Italy
Williamson Bradford
3Clinical Research, InterMune Inc., Brisbane, CA, United States
Ulrich Costabel
4Pneumologie/Allergie, Ruhrlandklinik, Essen, Germany
Talmadge King
5Department of Medicine, University of California San Francisco, CA, United States
Paul Noble
6Department of Medicine, Duke University School of Medicine, Durham, NC, United States
Steven Sahn
7Department of Medicine, Medical University of South Carolina, Charleston, SC, United States
Roland du Bois
8Department of Medicine, Imperial College, London, United Kingdom
Vol 40 Issue Suppl 56
Table of Contents
The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF)
Dominique Valeyre, Carlo Albera, Williamson Bradford, Ulrich Costabel, Talmadge King, Paul Noble, Steven Sahn, Roland du Bois
European Respiratory Journal Sep 2012, 40 (Suppl 56) P3159;